. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: Bioanalysis. 2014 Oct;6(20):2721–2732. doi: 10.4155/bio.14.139

Table 4.

Specificity: percentage difference in antiretroviral measured when lipemia present.

Analyte	N (values reported)	PD <±5 n(%)	PD ± 5–10 n(%)	PD >±10 n(%)	CPL^†
ATV	11	5 (45%)	5 (45%)	1 (10%)	-
DRV	14	8 (57%)	4 (29%)	2 (14%)	7
EFV	16	12 (75%)	3 (19%)	1 (6%)	-
FTC (1.6)	8	6 (75%)	2 (25%)	0 (-)	-
LPV	16	11 (69%)	4 (25%)	1 (6%)	-
NVP	5	2 (40%)	1 (20%)	2 (40%)	2,7^‡
RGV	10	7 (70%)	0 (-)	3 (30%)	7
RTV	15	7 (47%)	5 (33%)	3 (20%)	9
TFV	10	8 (80%)	0 (-)	2 (20%)	7
Total	105	66 (63%)	24 (23%)	15 (14%)	-

^†

Only if CPL consistently >±10 for two samples.

^‡

By design NVP not tested in duplicate for lipemia, thus only 1 value >±10.

%PD = ([lipemic value − control value]/control value) ×100

ARV: Antiretroviral; ATV: Atazanavir; CPL: Clinical pharmacology laboratory; DRV: Darunavir; EFV: Efaviren; FTC: Emtricitabine; LPV: Lopinavir; N: Number; NVP: Nevirapine; RGV: Raltegravir; RTV: Ritonavir; TFV: Tenofovir.